Search
Aurinia Pharmaceuticals Inc
AUPHAdd to Watchlist
16.400USD
-0.270-1.62%
Close 09-23 16:00（ET）
2.11BMarket Cap
7.36P/E TTM
Aurinia Pharmaceuticals Inc (AUPH) Stock Price Target & Forecast
Analyst Rating
Based on 7 analysts giving stock ratings to Aurinia Pharmaceuticals Inc in the past month.
Buy
1 Strong Buy
3 Buy
3 Hold
0 Sell
0 Strong Sell
Target Price
17.857USD+7.12%
AUPH Analyst Recommendation Trends
In the current month, AUPH has received 3 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. AUPH average Analyst price target in the last month is 17.857.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
1
1
1
1
1
1
1
2
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7
7
7
7
7
7
7
7
AUPH Analyst Rating for Peer Comparison
Updated: Sep 23, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Biogen Inc
BIIB
7
17
12
1
0
37
Amgen Inc
AMGN
4
12
18
2
1
37
Eli Lilly and Co
LLY
10
17
6
1
0
34
AbbVie Inc
ABBV
8
19
6
0
0
33
Merck & Co Inc
MRK
8
14
10
0
0
32
Vertex Pharmaceuticals Inc
VRTX
9
16
5
0
1
31
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Gilead Sciences Inc
GILD
7
18
6
0
0
31
Regeneron Pharmaceuticals Inc
REGN
6
14
10
0
0
30
Alnylam Pharmaceuticals Inc
ALNY
5
18
7
0
0
30
Financial Forecasting
Based on analysts' estimates, AUPH EPS is projected to reach 0.220 in FY2026Q3, following reported EPS of 0.288 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
0.22
0.20
0.24
0.22
0.20
Actual
1.60
0.26
0.29
--
--
Surprise
+637.15%
+31.08%
+19.84%
--
--
FAQs
What is Aurinia Pharmaceuticals Inc's expected revenue for the next quarter?
Aurinia Pharmaceuticals Inc's expected revenue is 83.69M.
What is Aurinia Pharmaceuticals Inc's price target?
Analysts forecast that Aurinia Pharmaceuticals Inc's price target is USD 17.86, with the highest forecast at USD 21.00 and the lowest forecast at USD 16.00.
How have Aurinia Pharmaceuticals IncAUPH's recent earnings per share performed?
The market expectation was USD 0.29, while Aurinia Pharmaceuticals IncAUPH's earnings per share (EPS) for the previous quarter was USD 0.26. EPS for the next quarter is expected at USD 0.22.
What is the analyst rating for Aurinia Pharmaceuticals Inc?
Based on the ratings of Aurinia Pharmaceuticals Inc's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.